Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDANTE II open-label extension
2011-000722-30Phase 2Completed
- Sponsor
- Pfizer
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pacibekitug in Crohn's disease, sponsored by Pfizer. Primary endpoints: Safety and tolerability and Immunogenicity. Started May 2011; status: completed.
02
Drugs
pacibekitug
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2011-000722-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000722-30.